Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis - PubMed
- ️Tue Jan 01 2013
Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis
Jarred W Rensvold et al. Cell Rep. 2013.
Abstract
Mitochondria are centers of metabolism and signaling whose content and function must adapt to changing cellular environments. The biological signals that initiate mitochondrial restructuring and the cellular processes that drive this adaptive response are largely obscure. To better define these systems, we performed matched quantitative genomic and proteomic analyses of mouse muscle cells as they performed mitochondrial biogenesis. We find that proteins involved in cellular iron homeostasis are highly coordinated with this process and that depletion of cellular iron results in a rapid, dose-dependent decrease of select mitochondrial protein levels and oxidative capacity. We further show that this process is universal across a broad range of cell types and fully reversed when iron is reintroduced. Collectively, our work reveals that cellular iron is a key regulator of mitochondrial biogenesis, and provides quantitative data sets that can be leveraged to explore posttranscriptional and posttranslational processes that are essential for mitochondrial adaptation.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.
Figures

(A) Experimental workflow for proteomic and microarray analysis of differentiated C2C12 mouse myotubes overexpressing PGC-1α and/or treated with 100 μM DFO. (B) Comparison of mRNA expression in GFP-treated cells and PGC-1α-treated cells (AU, arbitrary units). (C) Changes in protein expression during PGC-1α overexpression. Proteins are ordered from least to greatest fold change. (D) Comparison of mRNA expression in GFP-treated cells and DFO-treated cells. (E) Comparison of PGC-1α and DFO-induced changes in mRNA expression (59% of mitochondrial genes versus 18% of all genes are in the lower-right quadrant; p = 9.1 × 10−222, χ2 contingency test). (F) Comparison of OxPhos mRNA and protein expression during DFO treatment. (G) Mitochondrial mRNA and protein expression that show discordance during PGC-1α+DFO treatment. See also Figure S1 and Table S1.

(A) Level of the indicated proteins from samples used in the proteomic analyses as assessed by immunoblotting. (B) Abundance of the indicated transcripts from samples used in the microarray analyses as detected by real-time qPCR. Data are displayed as mean ± SD of triplicate measurements (*p < 0.05, ANOVA with Tukey's test). (C) Level of the indicated proteins in C2C12 myotubes after treatment with a range of DFO concentrations for 3 days as assessed by immunoblotting. (D) Level of the indicated proteins after DFO treatment for 24 hr in the indicated cell lines as assessed by immunoblotting. (E) Level of the indicated proteins after DFO treatment for 24 hr in C2C12 myoblasts as assessed by SDS-PAGE and immunoblotting. (F) Level of the indicated proteins after DFO treatment for 24 hr in myoblasts as assessed by BN-PAGE and immunoblotting (SC, respiratory supercomplex; NS, nonspecific band). (G) Mitochondrial mass in myoblasts after DFO treatment for 24hr as assessed by plate reader-based quantitation of MitoTracker Green FM or NAO fluorescence/cell number. Data are displayed as mean ± SD of triplicate measurements (NS signifies p ≥ 0.05, Student's t test). See also Figure S2.

(A–I) Immunoblotting was used to assess protein abundance, and real-time qPCR was used to assess mRNA abundance. Data are displayed as mean ± SD of triplicate measurements (*p < 0.05, Student's t test). (A) Protein levels in HEK293 cells after 100 μM DFO treatment or ferroportin (Fpn-GFP) over-expression for 48 hr. Abundance of (B) Ndufs8, (C) Uqcrc1, and (D) Ppargc1a in C2C12 myoblasts following DFO treatment for the indicated times. (E) Level of the indicated proteins in wild-type or PGC-1α−/− brown preadipocytes after 100 μM DFO treatment for 24 hr. (F) Abundance of Ppargc1b in myoblasts following DFO treatment for the indicated times. (G) Level of the indicated proteins in wild-type or PGC-1 bf/f/MLC-Cre soleus muscle primary satellite cells after 100 μM DFO treatment for 24 hr. (H) Level of the indicated proteins after 100 μM DFO, 100 μM DP, or 500 μM DMOG treatment for 24 hr in myoblasts. (I) Level of the indicated proteins in wild-type or HIF-1α −/− MEFs after 100 μM DFO treatment for 24 hr. See also Figure S3.

(A) Experimental workflow for the analysis of mitochondrial gene expression and respiration during DFO response and recovery. (B) Level of the indicated proteins in C2C12 myoblasts treated with 100 μM DFO for 24 hr then passaged every 24 hr in DFO-free media as assessed by immunoblotting. (C) Mitochondrial respiratory profile of untreated myoblasts at day 1 of analysis. Data are displayed as mean ± SD of 14–16 replicates. (D–F) Basal OCR (pmol/min)/cell number (D), spare respiratory capacity (E), and coupling efficiency (F) of myoblasts treated with 100 μM DFO for 24 hr then passaged every 24 hr in DFO-free media. Data are displayed as mean±SD of 14–16 replicates (*p<0.05, Student's t test in D, ANOVA with Tukey's test in E and F). See also Figure S4.
Similar articles
-
Mitochondrial biogenesis contributes to ischemic neuroprotection afforded by LPS pre-conditioning.
Stetler RA, Leak RK, Yin W, Zhang L, Wang S, Gao Y, Chen J. Stetler RA, et al. J Neurochem. 2012 Nov;123 Suppl 2(0 2):125-37. doi: 10.1111/j.1471-4159.2012.07951.x. J Neurochem. 2012. PMID: 23050650 Free PMC article.
-
Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes.
Hao J, Shen W, Yu G, Jia H, Li X, Feng Z, Wang Y, Weber P, Wertz K, Sharman E, Liu J. Hao J, et al. J Nutr Biochem. 2010 Jul;21(7):634-44. doi: 10.1016/j.jnutbio.2009.03.012. Epub 2009 Jul 2. J Nutr Biochem. 2010. PMID: 19576748
-
Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N. Morita M, et al. Cell Metab. 2013 Nov 5;18(5):698-711. doi: 10.1016/j.cmet.2013.10.001. Cell Metab. 2013. PMID: 24206664
-
O'Hagan KA, Cocchiglia S, Zhdanov AV, Tambuwala MM, Cummins EP, Monfared M, Agbor TA, Garvey JF, Papkovsky DB, Taylor CT, Allan BB. O'Hagan KA, et al. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2188-93. doi: 10.1073/pnas.0808801106. Epub 2009 Jan 28. Proc Natl Acad Sci U S A. 2009. PMID: 19179292 Free PMC article.
-
Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Chowanadisai W, et al. J Biol Chem. 2010 Jan 1;285(1):142-52. doi: 10.1074/jbc.M109.030130. Epub 2009 Oct 27. J Biol Chem. 2010. PMID: 19861415 Free PMC article.
Cited by
-
Herrmann AL, Kuhn BJ, Holzer A, Krijgsveld J, Hoppe-Seyler K, Hoppe-Seyler F. Herrmann AL, et al. Cancers (Basel). 2021 Oct 5;13(19):4995. doi: 10.3390/cancers13194995. Cancers (Basel). 2021. PMID: 34638479 Free PMC article.
-
Li H, Liu Y, Shang L, Cai J, Wu J, Zhang W, Pu X, Dong W, Qiao T, Li K. Li H, et al. Proc Natl Acad Sci U S A. 2019 May 14;116(20):9871-9876. doi: 10.1073/pnas.1820051116. Epub 2019 Apr 30. Proc Natl Acad Sci U S A. 2019. PMID: 31040213 Free PMC article.
-
Kallianpur AR, Jia P, Ellis RJ, Zhao Z, Bloss C, Wen W, Marra CM, Hulgan T, Simpson DM, Morgello S, McArthur JC, Clifford DB, Collier AC, Gelman BB, McCutchan JA, Franklin D, Samuels DC, Rosario D, Holzinger E, Murdock DG, Letendre S, Grant I; CHARTER Study Group. Kallianpur AR, et al. PLoS One. 2014 Aug 21;9(8):e103123. doi: 10.1371/journal.pone.0103123. eCollection 2014. PLoS One. 2014. PMID: 25144566 Free PMC article.
-
Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice.
Cloonan SM, Glass K, Laucho-Contreras ME, Bhashyam AR, Cervo M, Pabón MA, Konrad C, Polverino F, Siempos II, Perez E, Mizumura K, Ghosh MC, Parameswaran H, Williams NC, Rooney KT, Chen ZH, Goldklang MP, Yuan GC, Moore SC, Demeo DL, Rouault TA, D'Armiento JM, Schon EA, Manfredi G, Quackenbush J, Mahmood A, Silverman EK, Owen CA, Choi AM. Cloonan SM, et al. Nat Med. 2016 Feb;22(2):163-74. doi: 10.1038/nm.4021. Epub 2016 Jan 11. Nat Med. 2016. PMID: 26752519 Free PMC article.
-
Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.
Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G. Gammella E, et al. Oxid Med Cell Longev. 2015;2015:230182. doi: 10.1155/2015/230182. Epub 2015 Mar 24. Oxid Med Cell Longev. 2015. PMID: 25878762 Free PMC article. Review.
References
-
- Baltzer C, Tiefenböck SK, Frei C. Mitochondria in response to nutrients and nutrient-sensitive pathways. Mitochondrion. 2010;10:589–597. - PubMed
-
- Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol. 2003;73:200–210. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases